Coeptis Therapeutics (NASDAQ:ZSQR) Shares Up 13.4% – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR)’s stock price rose 13.4% during mid-day trading on Monday . The company traded as high as $12.40 and last traded at $12.40. Approximately 229,908 shares were traded during mid-day trading, an increase of 115% from the average daily volume of 106,765 shares. The stock had previously closed at $10.93.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Coeptis Therapeutics Price Performance

The company’s fifty day moving average is $11.89 and its 200 day moving average is $12.93. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. The stock has a market cap of $656.76 million, a PE ratio of -5.07 and a beta of -0.22.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The business had revenue of $0.11 million during the quarter.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC raised its holdings in Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after buying an additional 2,500 shares during the period. Yorkville Advisors Global LP purchased a new position in Coeptis Therapeutics in the third quarter valued at approximately $140,000. Marshall Wace LLP purchased a new position in Coeptis Therapeutics in the fourth quarter valued at approximately $259,000. State Street Corp boosted its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the period. Hedge funds and other institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.